Endocyte, Inc. (NASDAQ:ECYT)’s share price was up NaN during mid-day trading on Wednesday . The stock traded as high as $4.87 and last traded at $0.00. Approximately 710,442 shares were traded during trading, an increase of Infinity from the average daily volume of 0 shares.
Several equities analysts recently issued reports on ECYT shares. Zacks Investment Research cut Endocyte from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Wedbush upgraded Endocyte from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $2.00 to $7.00 in a research note on Tuesday, October 3rd. ValuEngine upgraded Endocyte from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd. Finally, Cowen and Company restated a “hold” rating on shares of Endocyte in a research note on Monday, October 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. Endocyte currently has an average rating of “Hold” and an average price target of $7.00.
Endocyte (NASDAQ:ECYT) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03). The firm had revenue of $0.01 million for the quarter. Endocyte had a negative net margin of 61,437.14% and a negative return on equity of 32.68%. During the same quarter in the previous year, the company posted ($0.25) EPS.
A number of hedge funds have recently made changes to their positions in ECYT. Stifel Financial Corp boosted its stake in Endocyte by 3.9% in the 1st quarter. Stifel Financial Corp now owns 45,353 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,711 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Endocyte by 34.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 25,003 shares in the last quarter. Spark Investment Management LLC acquired a new stake in Endocyte in the 2nd quarter valued at $177,000. LMR Partners LLP acquired a new stake in Endocyte in the 2nd quarter valued at $196,000. Finally, Ameriprise Financial Inc. boosted its stake in Endocyte by 26.7% in the 1st quarter. Ameriprise Financial Inc. now owns 133,270 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 28,110 shares in the last quarter. 25.58% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://sportsperspectives.com/2017/11/01/endocyte-inc-ecyt-trading-up-nan.html.
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.